Form 10-Q Annexon, Inc. For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
H.C. Wainwright Reiterates Buy Rating on Annexon Biosciences (ANNX)
August 13, 2024 6:20 AM EDTH.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $30.00 price target on Annexon Biosciences (NASDAQ: ANNX).
The analyst comments "Valuation and Risks. Our price target of $30 is based on an equally weighted composite of: (a) $31.56/share, as a 30x multiple taxed and... More



